Will the Capital Markets Open in 2025 for Life Sciences?
By

For the past several years, life science executives and investors alike have been asking the same question: when will the capital markets fully reopen?  After a challenging 2022–2023 cycle marked by inflation, rising interest rates, and geopolitical uncertainty, many hoped 2024 would bring a meaningful rebound. Instead, the year proved…Read More

Read More
Life Sciences Companies: Sell Now or Sell Later?
By

Life sciences companies in their early stages are in constant need of capital to continue along their path to meeting clinical milestones. Most are pre-revenue and focused on successful completion of Phase I and II clinical trials. And with strong clinical data, these investment prospects are attractive to sources of…Read More

Read More